SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.
Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025 Priority Review granted based on positive pivotal results demonstrat ...
Press Release: Dupixent Sbla Accepted For FDA Priority Review For The Targeted Treatment Of Bullous Pemphigoid
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid <li /> If approved, Dupixent would be the ...
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...
Sanofi: Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid
Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid If approved, Dupixent would be the first and only targeted medicine to treat BP in the US; FDA decision ...
EurekAlert!1d
A treatment-resistant, severe type of asthma successfully modeled in mice
A team of researchers at University of Michigan and Boston University are tackling neutrophilic asthma, successfully developing one of the first mouse models of the condition.
PharmiWeb6d
Aqilion carries out a rights issue of approximately SEK 26.8 million
The Board of Directors of Aqilion AB (publ) ("Aqilion" or the "Company") has on 11 February 2025, based on the authorization granted by the Annual General Meeting on 10 June 2024, resolved to carry ...
Revolo to Present at the 2025 AAAAI / WAO Joint Congress
GAITHERSBURG, Md. and CAMBRIDGE, United Kingdom, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Limited (“Revolo”) today announced that it will present two posters on its lead candidate, ‘1104, at the 2025 ...
pulmonologyadvisor13d
Guidance Developed for Diagnosis, Management of Eosinophilic Esophagitis
HealthDay News — In a clinical guideline issued by the American College of Gastroenterology and published in the January issue of the American Journal of Gastroenterology, recommendations are ...
AARP14d
Top Treatments for Thinning Hair After 50
Can be done at home. Cons: Costly. Must be used indefinitely. Evidence of efficacy is mixed. Cost: For at-home treatment, a one-time cost of $500 to $3,000 for the apparatus. What it is: A ...
New Food Magazine14d
New research uncovers molecular trigger for childhood food allergy disorder
Scientists have identified a key food allergen behind eosinophilic esophagitis, offering new hope for diagnosis and treatment ...
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...